Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H21ClO4 |
Molecular Weight | 360.831 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2
InChI
InChIKey=YMTINGFKWWXKFG-UHFFFAOYSA-N
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
Molecular Formula | C20H21ClO4 |
Molecular Weight | 360.831 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25903954
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25903954
Fenofibrate is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. It’s used as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is a fibric acid derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. Fenofibrate is rapidly hydrolyzed after oral ingestion to its pharmacologically active form, fenofibric acid. The effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII (an inhibitor of lipoprotein lipase activity), which increases lipolysis and elimination of triglyceride-rich particles from plasma. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. PPARα also increases apoproteins AI and AII, reduces VLDL- and LDL-containing apoprotein B, and increases HDL-containing apoprotein AI and AII.Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid. Fenofibrate also has an off-label use as uricosuric therapy in people who have gout.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25903954
Curator's Comment: fenofbrate cannot cross the blood-brain barrier and reach the central nervous system
Originator
Curator's Comment: Procetofen was synthesized in 1974 and was introduced in clinical practice in France the same year. Procetofen, which significantly decreased plasma lipid concentrations in hyperlipidemic patients, was later called fenofibrate to comply with World Health Organization nomenclature guidelines
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26693220 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TRICOR Approved UseTreatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides
and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment
Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with
hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Launch Date1.09952644E12 |
|||
Palliative | TRICOR Approved UseTreatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides
and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment
Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with
hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Launch Date1.09952644E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.96 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27648957 |
67 mg single, oral dose: 67 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
51.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27648957 |
67 mg single, oral dose: 67 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27648957 |
67 mg single, oral dose: 67 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16 h |
160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FENOFIBRIC ACID serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FENOFIBRIC ACID serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Other AEs: Asthenia, Pain... Other AEs: Asthenia (1.1%) Sources: Pain (1.1%) Headache (3.4%) Migraine (2.3%) Dyspepsia (2.3%) Gastrointestinal disorder (1.1%) Nausea (3.4%) Diarrhoea (1.1%) Myalgia (1.1%) Dizziness (1.1%) Abnormal thinking (1.1%) |
145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Other AEs: Abdominal pain, Back pain... Other AEs: Abdominal pain (4.6%) Sources: Back pain (3.4%) Headache (3.2%) Nausea (2.3%) Constipation (2.1%) Abnormal liver function tests (7.5%) ALT increased (3%) CPK increased (3%) AST increased (3.4%) Respiratory disorder (6.2%) Rhinitis (2.3%) Urticaria (1.1%) Rash (1.4%) |
200 mg 2 times / day multiple, oral Highest studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: |
unhealthy n = 46 Health Status: unhealthy Condition: hyperlipoproteinaemia Sex: M+F Population Size: 46 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abnormal thinking | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Asthenia | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Diarrhoea | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Dizziness | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Gastrointestinal disorder | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Myalgia | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Pain | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Dyspepsia | 2.3% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Migraine | 2.3% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Headache | 3.4% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Nausea | 3.4% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Urticaria | 1.1% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Rash | 1.4% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Constipation | 2.1% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Nausea | 2.3% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Rhinitis | 2.3% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
ALT increased | 3% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
CPK increased | 3% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Headache | 3.2% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
AST increased | 3.4% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Back pain | 3.4% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Abdominal pain | 4.6% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Respiratory disorder | 6.2% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Abnormal liver function tests | 7.5% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 3.0 |
moderate | |||
Page: 3.0 |
no | |||
Page: 3.0 |
no | |||
Page: 3.0 |
no | |||
Page: 3.0 |
no | |||
Page: 3.0 |
weak | |||
Page: 3.0 |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/26700956/ Page: 16.0 |
yes [IC50 170 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/ Page: 6.0 |
yes [IC50 2.39 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/14698041/ Page: 4.0 |
yes [IC50 5.83 uM] | |||
yes [Inhibition 50 uM] | ||||
yes [Ki 105.2 uM] | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/14698041/ Page: 1.0 |
no | |||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15304429/ Page: 3.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Severe toxic neuropathy due to fibrates. | 1999 Mar |
|
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? | 2000 Dec |
|
Advances in lipid-lowering therapy in atherosclerosis. | 2001 |
|
[New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis]. | 2001 |
|
Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. | 2001 Apr |
|
Peroxisome proliferator-activated receptor a ligands increase lectin-like oxidized low density lipoprotein receptor-1 expression in vascular endothelial cells. | 2001 Dec |
|
Treating lipid abnormalities in patients with type 2 diabetes mellitus. | 2001 Dec 20 |
|
Increasing high-density lipoprotein cholesterol: an update on fenofibrate. | 2001 Dec 20 |
|
Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography. | 2001 Jan |
|
Deterioration in renal function associated with fibrate therapy. | 2001 Jan |
|
The role of fibric acids in atherosclerosis. | 2001 Jan |
|
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. | 2001 Jan 1 |
|
Abundant expression of uncoupling protein-2 in the small intestine: up-regulation by dietary fish oil and fibrates. | 2001 Jan 15 |
|
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. | 2001 Jan 16 |
|
Fibrate-induced increase in blood urea and creatinine. | 2001 Jul |
|
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. | 2001 Mar |
|
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. | 2001 May 15 |
|
Choice of lipid-regulating drugs. | 2001 May 28 |
|
Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. | 2001 May 29 |
|
Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. | 2001 Oct |
|
Effects of fenofibrate on lipid parameters in obese rhesus monkeys. | 2001 Oct |
|
Fenofibrate: a new treatment for hyperuricaemia and gout? | 2001 Oct |
|
Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. | 2001 Sep |
|
Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. | 2001 Sep |
|
Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. | 2002 Feb |
|
Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha. | 2002 Jan |
|
Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats. | 2002 Jan |
|
Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease. | 2002 Jan 1 |
|
A laser flash photolysis study of fenofibric acid in aqueous buffered media: unexpected triplet state inversion in a derivative of 4-alkoxybenzophenone. | 2002 Mar |
|
Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation. | 2002 Mar |
|
Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes. | 2002 Mar 15 |
|
Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. | 2002 Mar-Apr |
Sample Use Guides
Primary Hypercholesterolemia or Mixed Hyperlipidemia: the initial dose of TRICOR (FENOFIBRATE TABLETS) is 145 mg per day
Hypertriglyceridemia: the initial dose is 48 to 145 mg per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27629528
Fenofibrate may protect against endothelin-1 (ET-1)-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiachypertrophy and heart failure.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 15:53:51 UTC 2022
by
admin
on
Fri Dec 16 15:53:51 UTC 2022
|
Record UNII |
U202363UOS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175375
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
WHO-VATC |
QC10BA03
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
WHO-ATC |
C10BA04
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
LIVERTOX |
NBK548607
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
NCI_THESAURUS |
C98150
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
WHO-VATC |
QC10AB05
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
WHO-ATC |
C10BA03
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
WHO-ATC |
C10AB05
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
WHO-VATC |
QC10BA04
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
NDF-RT |
N0000170118
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
NDF-RT |
N0000175596
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
||
|
NDF-RT |
N0000170118
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3996
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
U202363UOS
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
SUB07576MIG
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
7186
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
7736
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
C29047
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
49562-28-9
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
CHEMBL672
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
221100
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
DB01039
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
U202363UOS
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
256-376-3
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
5001
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
Fenofibrate
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
1269447
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
D011345
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
1152
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
8703
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
ALTERNATIVE | |||
|
FENOFIBRATE
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
M5279
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | Merck Index | ||
|
DTXSID2029874
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY | |||
|
3339
Created by
admin on Fri Dec 16 15:53:51 UTC 2022 , Edited by admin on Fri Dec 16 15:53:51 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||